New Technology for Noninvasive Evaluation of Coronary Artery Disease

M Di Carli and R Hachamovitch |  Mar 20, 2007

This review paper discusses current and potential future applications of cardiovascular CT, PET and hybrid PET/CT, with a particular focus on ischemic heart disease.

For Intravenous Use


Ammonia N 13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.


Radiation Risks: Ammonia N 13 Injection may increase the risk of cancer. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker.


Adverse Reactions: No adverse reactions have been reported for Ammonia N 13 Injection based on a review of the published literature, publicly available reference sources and adverse drug reaction reporting systems. However, the completeness of these sources is not known.

Siemens' PETNET Solutions is a manufacturer of Ammonia N 13 Injection. Indication and important safety information as approved by the US Food and Drug Administration can be found at the links below for 13N Ammonia, adult dose 8-12 mCi, administered by intravenous injection.

Related Articles